198 related articles for article (PubMed ID: 20957481)
1. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.
Montemurro M; Schöffski P; Reichardt P; Gelderblom H; Schütte J; Hartmann JT; von Moos R; Seddon B; Joensuu H; Wendtner CM; Weber E; Grünwald V; Roth A; Leyvraz S
Eur J Cancer; 2009 Sep; 45(13):2293-7. PubMed ID: 19467857
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A
Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
[TBL] [Abstract][Full Text] [Related]
7. Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.
Dizdar O; Yalcin S
Hepatogastroenterology; 2011; 58(107-108):859-60. PubMed ID: 21830404
[TBL] [Abstract][Full Text] [Related]
8. Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy.
Dizdar O; Yalcin S
Hepatogastroenterology; 2011; 58(112):2012-4. PubMed ID: 22024073
[TBL] [Abstract][Full Text] [Related]
9. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
Li J; Gao J; Hong J; Shen L
Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
Yoon DH; Ryu MH; Ryoo BY; Beck M; Choi DR; Cho Y; Lee JL; Chang HM; Kim TW; Kang YK
Invest New Drugs; 2012 Apr; 30(2):819-27. PubMed ID: 21104107
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
George S; Blay JY; Casali PG; Le Cesne A; Stephenson P; Deprimo SE; Harmon CS; Law CN; Morgan JA; Ray-Coquard I; Tassell V; Cohen DP; Demetri GD
Eur J Cancer; 2009 Jul; 45(11):1959-68. PubMed ID: 19282169
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Demetri GD; van Oosterom AT; Garrett CR; Blackstein ME; Shah MH; Verweij J; McArthur G; Judson IR; Heinrich MC; Morgan JA; Desai J; Fletcher CD; George S; Bello CL; Huang X; Baum CM; Casali PG
Lancet; 2006 Oct; 368(9544):1329-38. PubMed ID: 17046465
[TBL] [Abstract][Full Text] [Related]
15. Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Sevinc A
Chemotherapy; 2009; 55(2):132-6. PubMed ID: 19188713
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Montemurro M; Gelderblom H; Bitz U; Schütte J; Blay JY; Joensuu H; Trent J; Bauer S; Rutkowski P; Duffaud F; Pink D
Eur J Cancer; 2013 Mar; 49(5):1027-31. PubMed ID: 23140824
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L
Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
Cauchi C; Somaiah N; Engstrom PF; Litwin S; Lopez M; Lee J; Davey M; Bove B; von Mehren M
Cancer Chemother Pharmacol; 2012 Apr; 69(4):977-82. PubMed ID: 22119758
[TBL] [Abstract][Full Text] [Related]
19. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Joensuu H; De Braud F; Grignagni G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG
Br J Cancer; 2011 May; 104(11):1686-90. PubMed ID: 21540861
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches to imatinib- and sunitinib-resistant GIST.
Reichardt P
Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
